Enfusion

Enfusion Net Debt / EBITDA

Delisted

The Net Debt to EBITDA of Enfusion (ENFN) as of Nov 7, 2026 is -8.85. In the previous year, Net Debt to EBITDA was -2.98 — a change of 197.03% (lower).

Net Debt / EBITDA

-8.85

YoY

197.03%

Last updated:

Net Debt to EBITDA of Enfusion is 2024 -8.85 . Net Debt to EBITDA of Enfusion was 2023 -2.98 . It decreases by 197.03% lower compared to the previous year.

The Enfusion Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
1.57 USD
Jan 1, 2020
13.94 USD
Jan 1, 2021
0.23 USD
Jan 1, 2022
5.23 USD
Jan 1, 2023
-2.98 USD
Jan 1, 2024
-8.85 USD
The Enfusion Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-8.85+197.03%
-2.98-157.00%
5.23+2,150.37%
0.23-98.33%
13.94+786.67%
1.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enfusion Stock analysis

What does Enfusion do? Enfusion Inc. generates revenue through cloud-native multi-tenant software solutions tailored for alternative and institutional investment managers. Its core products include the Portfolio Management System (PMS), Order and Execution Management System (OEMS), Accounting/General Ledger System, and Enfusion Analytics System, which collectively enable real-time investment decision-making. The company serves investment managers who require integrated systems for the full investment lifecycle, with PMS constructing and rebalancing portfolios while generating a real-time investment book of record, and OEMS facilitating electronic trade order communication for portfolio managers, traders, compliance teams, and analysts. The company's solution integrates technology-powered managed services to drive insights and control over investment operations. Enfusion's end-to-end functionality supports the entire investment process, from portfolio construction to trade execution, with PMS and OEMS operating in tandem to provide a seamless workflow. Investment managers across alternative and institutional segments purchase these integrated systems to enhance operational efficiency and decision-making capabilities. Enfusion's software is designed to serve the full investment lifecycle, with its systems integrated to provide a unified platform for portfolio management, order execution, accounting, and analytics. The company's revenue model is based on delivering these comprehensive solutions to investment managers who rely on real-time data and integrated workflows to manage their operations effectively. Enfusion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enfusion stock

Net Debt to EBITDA of Enfusion is -8.85 in 2024.

Net Debt to EBITDA of Enfusion changed from -2.98 to -8.85, representing a 197.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Enfusion since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Enfusion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Enfusion

All Key Metrics — Enfusion